Marijuana addiction attracts drug makers to find cures
A large pharmaceutical company specializing in solving problems with various kinds of drug addiction from an economically developed country of the world directs significant financial resources to research aimed at creating pharmacological preparations designed to prevent or suppress addictions that arise during the regular use of the psychoactive component of cannabis.
Our colleagues who specialize in the field of the use of the hemp plant in the recreational field constantly emphasize that there is no evidence that marijuana negatively affects the human body. It would be difficult to argue with such statements without specific arguments based on the results of relevant studies conducted in economically developed countries of the world, therefore, on the pages of the specialized electronic edition of national cannabis growers in the material “ Recommendations of US doctors on the use of therapeutic components of cannabis”Already described the findings of US experts officially published in the American Journal of Public Health back in 2017. It also highlighted new research showing that " Cannabis is almost as addictive in adolescents as opioids ." Due to the fact that there is a trend in the world, according to which in many states opportunities for the use of the plant for recreational purposes are opening up, there is growing concern in the government structures of individual countries about the growth of addiction caused by the regular use of the psychoactive component of the hemp plant. This kind of concern is already being transformed into the interest of business structures to solve an emerging, but still hushed up problem. This material deals with how individual companies are preparing to fulfill the need to prevent or suppress dependence on the use of psychoactive constituents of the hemp plant by channeling resources into the development of pharmacological drugs aimed at solving this problem.
The British company "Indivior Plc", which produces drugs for various types of addiction (opioid, cocaine, alcohol), has partnered with the French biotechnology firm "Aelis Farma" to begin an interim study of therapy aimed at helping with the disease known as the disorder. associated with cannabis use. The agreement provides for a one-time payment to Aelis Farma of $ 30 million and allows Indivior Plc to buy out the rights to the created drug for $ 100 million at a later date, along with possible interim payments and royalties if the test of the created drug is successful.
Indivior Plc's management has become at the forefront of a number of research and pharmaceutical companies seeking to address the growing problem of a lack of FDA-approved drugs for the treatment of drug addiction. the use of the psychoactive component of cannabis.
In particular, according to Mark Crossley, Chief Executive Officer of Indivior Plc, “Marijuana is the most common drug of abuse outside of alcohol and tobacco, and there is no FDA-approved drug to address these addictions, which is a huge concern if we look closely at the trends. where cannabis use is heading in general ”. According to Mr. Crosley, the market for drugs intended for the treatment of addiction to marijuana in the coming years will “amount to several billion dollars. The growing activity in the use of psychoactive cannabis, which he estimates has increased fivefold over the past few decades, means that people are now much more likely to develop marijuana-related disorders than they were in the past. ”
Christian Heidbroeder, chief scientist at Indivior Plc, claims that the drug under development targets the brain receptors that are affected by the psychoactive ingredient in cannabis. Research on its development and registration will take at least 5 years.
Commentary of the specialists of the Association "Ukrainian technical hemp"
According to the specialized electronic resource clinicaltrials.gov, at the moment there are about 70 registered studies aimed at finding pharmacological drugs designed to solve problems with various disorders (including addictions) caused by the use of psychoactive cannabis. The American National Institute for Drug Abuse, citing research, claims that between 9% and 30% of people who use marijuana can become drug addicts.
Indivior Plc was founded as a buprenorphine division of Reckitt Benckiser in 1994. In December 2014, Reckitt Benckiser spun off its specialty pharmaceuticals business into a separate company called Indivior Plc. By February 2015, the capitalization of Indivior Plc on the London Stock Exchange had already reached $ 3.1 billion. The main products of the company are Subutex and Suboxone - both drugs that replace opioid addiction. Other products of the company include remedies for cocaine and alcohol addiction.
We emphasize that a large pharmacological company specializing in solving problems with various kinds of drug addiction from an economically developed country of the world directs significant financial resources to research aimed at creating pharmacological drugs designed to prevent or suppress addictions that arise during the regular use of psychoactive constituent of cannabis. The decision on this kind of investment is not made on the basis of rumors, speculation or guesswork. At least the analysts of "Indivior Plc" put on the table of the company's management research on the emergence of addiction in cases of the use of psychoactive components of marijuana and the indicators of the market that already exists or is being formed at the moment with a forecast of its significant increase. Only on the basis of this kind of materials can decisions be made about investments in the amount of millions of dollars in drugs that will be intended to solve the problem "which does not exist."